We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Hypoxia-activated prodrugs forge ahead in cancer.
- Authors
Kling, Jim
- Abstract
The article reports on the deal signed by Merck KGaA with Threshold Pharmaceuticals for the joint development and commercialization of TH-302, a 2-nitroimidazole-triggered bromo analog of the deoxyribonucleic acid (DNA)-alkylating agent ifosfamide. John Gutheil of ProActa explains the basis of the Merck-Threshold deal. Information on the results of Threshold's Phase II trial of TH-302 is provided, along with the concept behind hypoxia-activated prodrugs.
- Subjects
RESEARCH &; development contracts; MERCK KGaA; THRESHOLD Phramaceuticals (Company); DRUG development; COMMERCIALIZATION; CLINICAL trials; ANTIBODY-directed enzyme prodrug therapy; GUTHEIL, John
- Publication
Nature Biotechnology, 2012, Vol 30, Issue 5, p381
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0512-381